Molecular and Cellular Biology, January 2002, p. 378-387, Vol. 22, No. 1
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.22.1.378-387.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Zhengping Jia,2 Yu Zhang,2 Jerry Ware,3 and William S. Trimble1*
Programmes in Cell Biology,1 Brain and Behavior, Hospital for Sick Children, Toronto, Ontario, Canada M5G 1X8,2 The Scripps Research Institute, La Jolla, California 920373
Received 18 July 2001/ Returned for modification 10 September 2001/ Accepted 3 October 2001
|
|
|---|
|
|
|---|
The conserved requirement for septins in cell division was revealed by the discovery that the peanut gene in Drosophila melanogaster encoded a septin homolog (30). peanut mutations result in the formation of multinucleated syncytia in imaginal discs during larval development due to failure to complete cytokinesis. Antibodies to the peanut protein (pnut) revealed that it accumulated at the invaginating cleavage furrow in cells undergoing mitosis (30). As in yeast, Drosophila septins appear to associate as part of a complex since immunoisolated pnut copurifies with two other septins, Sep1 and Sep2, in stoichiometric ratios. In addition, these septins can also be induced to polymerize in vitro (10).
In humans there are at least 11 different septin genes, many of which also appear to undergo alternative splicing to produce multiple protein products (11, 20, 27, 38). As in yeast and Drosophila, a primary function of at least some septins appears to be in the process of cytokinesis. For example, injection of antibodies against a ubiquitously expressed mammalian septin, Nedd5, led to the failure of cytokinesis and the appearance of multiple nuclei within injected cells (23). The perturbation of septin gene products has also been linked to several cancers (33, 36). However, it is unlikely that the only function for mammalian septins is in cytokinesis since many forms are abundantly expressed in tissues such as the brain and heart that are predominantly nonmitotic. As well, some septin genes, such as the CDCrel-1 gene, are almost exclusively expressed in the brain (2, 5, 41). Analysis of such specialized forms may shed light on the general function of septins and thereby clarify their role in cytokinesis.
CDCrel-1, also known as PNUTL1 due to its homology with Drosophila pnut, was originally identified as a novel 42-kDa protein recognized by monoclonal antibodies raised against proteins associated with immunoprecipitated human synaptophysin (16). The relationship between CDCrel-1 and the septins was discovered when it was subsequently cloned in two independent studies. In the first study, CDCrel-1 was found as the upstream part of a fusion transcript containing the ß-subunit of the glycoprotein 1b platelet receptor (43) due to its nonconsensus polyadenylation sequence. As well, CDCrel-1 was identified as a gene within the segment of chromosome 22q11.2 that is commonly deleted in velo-cardiofacial and DiGeorge syndromes in humans (28). The latter is a complex congenital disorder including parathyroid and thymic hypoplasia as well as defects of the heart, which results, in part, in impaired migration of neural crest cells into the pharyngeal arches and pouches. The contribution of CDCrel-1 deficiency to the complexity of these phenotypes is not known.
CDCrel-1 shares a high level of homology (40 to 76% sequence identity) with other mammalian septins and also contains the highly conserved GTPase motifs. In the brain, CDCrel-1 is physically associated with synaptic vesicles as well as other membrane fractions (2) and is localized in presynaptic terminals (22). It has previously been shown, by immunoprecipitation experiments and by affinity binding studies using a glutathione S-transferase fusion protein, that CDCrel-1 interacts directly with the target membrane SNARE syntaxin 1A. Overexpression of wild-type CDCrel-1 in HIT-T15 cells inhibited evoked secretion, whereas a predicted dominant-negative form mutated in the GTPase domain enhanced secretion (2). Since septins appear filamentous, and their GTPase domain may contribute to this filamentous appearance, these observations suggest that septin filaments may regulate exocytosis by acting as a physical barrier to release.
Recently, CDCrel-1 was shown to be a direct substrate of the ring finger protein Parkin, an E3 ubiquitin ligase that is a causative agent in autosomal recessive forms of Parkinsons disease (7). Wild-type Parkin binds to and ubiquitinates CDCrel-1, leading to its degradation, whereas familial linked Parkin mutants are defective in the degradation of CDCrel-1 (42). Failure to degrade CDCrel-1 through the ubiquitin-mediated proteasome pathway could lead to reduced exocytosis of dopamine-containing synaptic vesicles and thus contribute to the development of Parkinsons disease.
To further investigate the function of CDCrel-1, we characterized its developmental expression in the brain and its association with other septins. In addition, we created targeted insertions in the gene to determine the loss-of-function phenotype. Despite our in vitro evidence that it had an important function in secretion, disruption of the CDCrel-1 locus did not cause any obvious developmental abnormalities, nor did the loss of CDCrel-1 perturb brain function significantly. The lack of an observable phenotype may be due to compensatory changes in the expression of other septins within the brain.
|
|
|---|
![]() View larger version (51K): [in a new window] |
FIG. 3. Generation of CDCrel-1-deficient mice by homologous recombination. (A) Construction of targeting vector. Schematic representation of the CDCrel-1 protein (top) and the wild-type genomic locus, showing the targeting vector and targeted genomic locus. The location of the probes used for Southern blotting to identify targeting events are shown below the protein. Exons are indicated by grey boxes, and exons 1 to 3 are not shown. The restriction enzymes indicated are BglII (Bgl), EcoRI (R1), HindIII (H3), XhoI (Xho), and SalI (Sal). (B) Southern blots of DNA extracted from mouse tails. Genomic DNA digested with BglII and probed with the 5' probe reveals the presence of the neo cassette replacing exons 4 to 6. The BglII fragment on the wild-type CDCrel-1 locus is approximately 16.5 kb while the 5' BglII fragment of the targeted CDCrel-1 locus is approximately 9.5 kb. (C) Mutant mice lack the CDCrel-1 protein. Western blots show 10 µg of protein extracted from total brain electrophoresed and probed with anti-CDCrel-1 monoclonal antibody. Chimeras were generated from two independent ES clones (4-2G and 4-4B), and the progeny of both were tested. A reduction in CDCrel-1 levels is apparent in heterozygotes, and the signal is absent from homozygous mutant mice even after prolonged exposure.
|
Immunoblotting analysis.
To analyze CDCrel-1 expression, brains were removed from mice and homogenized with a glass-Teflon homogenizer in 2 ml of ice-cold H buffer (10 mM HEPES-KOH [pH 7.5], 0.32 M sucrose, 1 mM MgCl2, 0.1 mM EGTA) in the presence of protease inhibitors (0.3 mM phenylmethylsulfonyl fluoride, 1 µg of leupeptin/ml, 1 µg of pepstatin/ml). The concentrations of the protein samples were determined by bicinchoninic acid assay (Pierce, Rockford, Ill.). Proteins (5 to 40 µg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and blotted on Immobilon-P membranes (Millipore, Bedford, Mass.) as described previously (2). The following primary antibodies were used in the immunoblotting experiments: mouse anti-CDCrel-1 (5), rabbit anti-CDCrel-1 (fetal), rabbit anti-Nedd5, rabbit anti-hCDC10, rabbit anti-H5, rabbit anti-VAMP2, mouse anti-
-subunit CaM kinase II (Affinity Bioreagents, Inc., Golden, Colo.), mouse anti-Sec8 (kindly provided by S. C. Hsu, Rutgers University), and mouse anti-PSD-95 (Chemicon, Temecula, Calif.).
Subcellular fractionation and immunoprecipitation. Brains were removed from five wild-type and five mutant mice and homogenized in 20 ml of H buffer as described above. The homogenate was then fractionated by differential centrifugation as previously described (18), and protein concentrations were determined for each fraction. Briefly, crude homogenates were spun at 800 x g to remove large unlysed cells and nuclei, and the pellet, P1, was discarded. The supernatant, S1, was then spun at 9,000 x g, and the synaptosome-enriched pellet was washed and repelleted (P2). The supernatant was collected (S2) and subjected to a high-speed spin at 100,000 x g to collect the high-speed pellet (P3) and the cytosolic fraction (S3). The P2 fraction was lysed by the addition of ice-cold water and sedimented first at 25,000 x g to collect the membrane-enriched pellet (LP1). The supernatant (LS1) was then sedimented at high speeds to produce the LP2 pellet that is enriched in synaptic vesicles. An equal amount of protein from each fraction was separated by SDS-PAGE and analyzed by Western blotting. For immunoprecipitations, the P2 fraction (synaptosome-enriched fraction) was first solubilized by the addition of n-octylglucoside to a concentration of 2% and incubated for 2 h at 4°C. Soluble material was then collected by centrifugation at 30,000 x g for 15 min, and the supernatant was mixed with protein A- or protein G-agarose beads coupled with septin antibodies for 2 h at 4°C. The agarose beads were washed 4 times with HKA buffer containing 0.1% Triton X-100 and 5% glycerol. Immunoprecipitates were eluted with nonreducing SDS sample buffer in the presence of 10 mM N-ethylmaleimide to prevent immunoglobulin dissociation and heavy chain contamination and analyzed by SDS-PAGE and Western blotting.
Hippocampal neuron culture. Postnatal hippocampal cell cultures were prepared from 1- to 2-day-old mice as described previously (19). Hippocampi were dissected and treated with papain (20 U/ml in neurobasal A medium) at 37°C for 30 min. Dissociated cells were plated at a low density on poly-D-lysine-coated glass coverslips in plating medium (neurobasal A plus B27 and supplemented with 0.5 mM L-glutamine and 25 µM L-glutamate [Life Technologies, Rockville, Md.]) for 2 h to allow the cell to adhere to the coverslips. Plating medium was removed and replaced with fresh feeding medium containing 25 µM glutamate and 5 ng of ß-fibroblast growth factor/ml. The feeding medium was changed every 4 days. Cultured 11-day neurons were fixed in 4% paraformaldehyde and 0.1% glutaraldehyde in phosphate-buffered saline (PBS) for 15 min and then quenched by 25 mM glycine-PBS for 10 min. The coverslips were washed twice with PBS and then permeabilized with PBS containing 0.5% Triton X-100. After blocking with PBS containing 1% bovine serum albumin and 0.1% nonfat powdered milk, the coverslips were incubated with primary antibody overnight at 4°C. Secondary antibodies were then added after 3 washes with PBS (5 min/wash) and incubated for 1 h at room temperature. Coverslips were washed three times with PBS and then mounted in antifade mounting medium (Molecular Probes, Eugene, Oreg.), and the images were processed by confocal microscopy.
Hippocampal slice recording. The procedure for electrophysiological recordings was described previously (19). Briefly, hippocampal slices (400 µm thick) were prepared from 2- to 3-month-old mice and allowed to recover for at least 1 h in a holding chamber filled with artificial cerebrospinal fluid (ACSF) saturated with 95% O2-5% CO2. A single slice was then transferred to a recording chamber (28 ± 0.5°C) where it was submerged and superfused with ACSF (2 ml/min). ACSF contained the following: 125 mM NaCl, 2.5 mM KCl, 1.6 mM MgSO4, 1.2 mM NaH2PO4, 26.2 mM NaHCO3, 2.0 mM CaCl2, and 10 mM d-glucose. Field excitatory postsynaptic potentials (fEPSPs) were evoked at a frequency of 0.03 Hz by bipolar tungsten electrodes and recorded with micropipettes filled with ACSF. The responses were amplified with an Axoclamp 2B and analyzed using pCLAMP 7 software (Axon Instruments, Union City, Calif.). The field potentials were measured by taking the slopes of the rising phase between 10 and 90% of the peak response and were verified by the addition of 5 µM 6-nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-dione at the end of each experiment. The stimulation intensity was adjusted to obtain approximately 25 to 30% of the maximum response.
|
|
|---|
![]() View larger version (69K): [in a new window] |
FIG. 1. Developmental expression of CDCrel-1 in the mouse brain. Brains were isolated from embryonic (embryonic day 17 [E17]) and postnatal (postnatal day 5 [P5], P7, P10, P15, and adult) mice. Total homogenates were prepared for each, and 40 µg of protein was electrophoresed and blotted with antibodies specific to the proteins indicated at the right.
|
![]() View larger version (60K): [in a new window] |
FIG. 2. CDCrel-1 coimmunoprecipitates with other brain septins. The P2 fraction from a mouse brain homogenate (18) was prepared and solubilized with n-octylglucoside, and then it was centrifuged to separate the soluble and insoluble proteins (left side of blot). The soluble fraction was then used as the starting material for immunoprecipitations with the antibodies indicated above the right portion of the blots. Precipitates were electrophoresed under nonreducing conditions and probed with the antibodies indicated at the right. Control immunoglobulin G (IgG) was nonspecific rabbit serum. Reactivity to the free heavy chain was observed in the anti-CDC10 immunoprecipitation lanes (bottom two blots) and in the IgG lane (bottom blot) because these were crude sera, but these were located above the septin bands. No reactivity was seen on the top blot since the blotting antibody was from a mouse. Of the n-octylglucoside soluble material used for the immunoprecipitations, 2% was loaded in the first lane.
|
Generation of CDCrel-1-deficient mice. To directly examine the function of CDCrel-1 in vivo, we generated mice with a targeted mutation in the CDCrel-1 gene. Genomic clones of the murine CDCrel-1 gene were obtained from a 129/SvJ mouse ES library and were used for the construction of a targeting vector. This vector was designed to permit the replacement of exons 4, 5, and 6 with a neo cassette (Fig. 3A). These three exons encode amino acids 19 to 92 of CDCrel-1, including the P loop consensus sequence found in all GTPases. Of 600 neomycin-resistant ES cell lines analyzed, two demonstrated the desired replacement mutation as determined by Southern blotting. These two clones were both used to generate chimeric founder mice and heterozygous mice in the F1 generation, as identified by Southern blotting of genomic DNA derived from the tail (not shown). Heterozygotes were then crossed to produce homozygous CDCrel-1-deficient mice. A typical Southern blot of wild-type, heterozygous, and homozygous deficient mice obtained from one of the ES lines is shown in Fig. 3B.
To confirm the lack of CDCrel-1 protein in the knockout mice, we probed brain tissue for the expression of CDCrel-1 using two different antibodies. The first was the monoclonal antibody that recognizes an epitope within the carboxyl terminal half of the protein. As shown in Fig. 3C, no protein could be detected in the homozygous deficient mice and levels appear reduced in the heterozygotes. We also probed blots with a polyclonal antibody raised to the first 15 amino acids of the fetal form of CDCrel-1 and detected no product in the mice (data not shown).
CDCrel-1-deficient mice have no gross developmental abnormalities. CDCrel-1-deficient mice were obtained with the expected Mendelian frequencies in both sexes. Deficient mice developed at the same rate as their littermates and displayed identical adult weights (not shown). Deficient mice were also fertile with litters of the normal size. Since CDCrel-1 is predominantly expressed in the brain, we examined the morphology of brain sections by hematoxylin and eosin staining. No significant differences were seen in the thickness of cortical layers, the appearance or location of nuclei, or in any other aspect of the gross morphology of the brain in any of the regions analyzed, including the hippocampus (not shown). These results indicate that CDCrel-1 is not required for normal development of the central nervous system or metabolic processes in mice. Several other tissues were also examined using hematoxylin- and eosin-stained paraffin-embedded sections, and these tissues included the pancreas, heart, lung, testis, and bone marrow. However, no abnormal morphology was observed.
Primary cultures of hippocampal neurons from CDCrel-1-deficient mice appear normal. The expression of CDCrel-1 at the time of synaptogenesis raised the possibility that it may participate in some aspect of neurite outgrowth such as the development of neuronal polarity or synapse formation. We therefore established primary cultures of hippocampal neurons from CDCrel-1-deficient mice and their wild-type littermates. At all stages of in vitro culture, the staining of CDCrel-1 was absent in all cells positive for the glial cell marker and present in cells that were positive for MAP2 and VAMP-2, suggesting that CDCrel-1 is only expressed in neurons. The 11-day in vitro cultures were stained with antibodies to CDCrel-1 and with antibodies to the synaptic vesicle protein VAMP-2. As shown in Fig. 4, wild-type hippocampal neurons produce extensive dendritic branches that are decorated with synapses, as judged by immunostaining for the presynaptic terminal marker VAMP-2. CDCrel-1 can be seen both throughout the dendrites and cell body but also concentrated in the puncta. As seen in the overlay image, both punctate patterns colocalize. CDCrel-1 staining is clearly within close proximity to that of VAMP-2, but it is difficult to determine if it is within presynaptic or postsynaptic structures. However, it had previously been shown that CDCrel-1 associated biochemically with synaptic vesicles, and more recent ultrastructural analysis localized CDCrel-1 among synaptic vesicles in the presynaptic nerve terminal (22) using immunoelectron microscopy, supporting the idea that these two proteins colocalize. In cultures established from the CDCrel-1-deficient mice, there appeared to be normal numbers of synaptic structures detected by VAMP-2 staining, and these appeared to be properly distributed over the surface of the dendrites (Fig. 4). CDCrel-1 staining confirmed the lack of expression of this septin because only background fluorescence could be detected in the images. Hence, CDCrel-1 appears to be dispensable for the formation of dendrites and synapses on hippocampal neurons in vitro.
![]() View larger version (70K): [in a new window] |
FIG. 4. Hippocampal neurons from CDCrel-1-deficient mice appear normal in vitro. Primary cultures were prepared from the hippocampi of CDCrel-1-deficient mice (mt) and their wild-type littermates (wt). After 11 days in vitro, the cells were fixed and stained with antibodies against CDCrel-1 (red) and VAMP-2 (green). Confocal images were collected and shown. CDCrel-1-deficient neurons had only background labeling due to the secondary antibody. The merged images are shown in the overlay column.
|
![]() View larger version (25K): [in a new window] |
FIG. 5. Electrophysiology of hippocampal slices from CDCrel-1-deficient mice. (A) Normal paired-pulse facilitation in CDCrel-1-deficient mice. The plot summarizes facilitation of the second fEPSP slope compared to the first one as a function of the interpulse interval. (B) Normal posttetanic potentiation in CDCrel-1-deficient mice. Brief (1 s) 100-Hz stimulation was given at the zero time point in the presence of 50 µM (-)-2-amino-5-phosphonopentanoic acid, and the fEPSPs were recorded immediately after the tetanus. (C) Synaptic depression in response to sustained synaptic activities in the knockout mice. Repetitive stimuli (5 Hz, lasting 120 s) were applied at the zero time point, and the fEPSP to each stimulus was recorded. Each data point represents the averaged slope of 20 responses (2 s). (D) Hippocampal CA1 LTP. LTP was induced by tetanic stimulation consisting of 2 trains of 100 Hz lasting 1 s, at an intertrain interval of 10 s, delivered at the zero time point. Above the plot are the representative traces (average of 4 sweeps) of fEPSP obtained immediately before (trace 1) and 50 min after (trace 2) the tetanic stimulation.
|
Finally, we examined the capability of CDCrel-1-deficient mice to acquire the long-lasting enhancement of synaptic activity often associated with increased efficacy of postsynaptic receptors. Hippocampal long-term potentiation (LTP) is a widely studied form of synaptic plasticity that requires activation of the N-methy-D-aspartic acid subtype of postsynaptic receptors. LTP was generated by delivering two trains of 100-Hz stimuli of 1-s duration separated by a 10-s interval. As shown in Fig. 5D, both CDCrel-1-deficient and wild-type littermates exhibited a very similar 40% increase in fEPSPs that lasted well beyond the 1-h course of the experiment. Taken together with the other physiological studies done, these results indicate that the absence of CDCrel-1 does not cause a significant change in the physiological properties of the synapse.
Changes in septin expression correlate with CDCrel-1 deficiency. In order to explain the absence of a physiological correlate for the lack of CDCrel-1 protein, we examined the expression of a number of synaptic proteins. If septins form filaments in the presynaptic terminal that function as tethers for synaptic vesicles, the absence of septin complexes might lead to subtle changes of synaptic vesicle distribution. Such changes may be detected by examining the synaptic proteins in different membrane fractions. Brains from CDCrel-1-deficient mice and their wild-type littermates were fractionated according to the procedure of Huttner et al. (18) to prepare crude membrane, synaptosomal, cytosolic, and synaptic vesicle fractions. All lanes were confirmed to contain equivalent amounts of protein by Ponceau S staining and by parallel blots for tubulin (not shown). The septin CDC10 had previously been identified within the postsynaptic density in proteomic studies of this protein complex (40). To determine if the lack of CDCrel-1 altered this structure, we examined the postsynaptic density proteins PSD-95 and CaMKII. The protein Sec8, a component of the mammalian exocyst complex, was monitored because previous studies had demonstrated an association between this protein and the septins (17). Finally, we examined the presence and fractionation of the synaptic vesicle protein VAMP-2 as a marker for synaptic vesicles. As shown in Fig. 6A, neither the levels of nor fractionation of any of these proteins was affected by the absence of CDCrel-1. Other presynaptic proteins were also examined, including syntaxin, SNAP-25 and nsec1, but no changes were noted between wild-type and deficient mice in their distribution either (data not shown).
![]() View larger version (72K): [in a new window] |
FIG. 6. Altered expression of septins, but not other synaptic proteins, in the brains of CDCrel-1-deficient mice. Wild-type and CDCrel-1-deficient brains were fractionated according to the procedure of Huttner et al. (18), and 20 µg of protein from each fraction was loaded onto each lane. Lanes: H, total homogenate; S1, low-speed supernatant; P2, crude synaptosomal fraction; P3, high-speed pellet of synaptosome-depleted sample; S3, cytosolic high-speed supernatant; LP1, low-speed pellet of lysed synaptosome containing membrane fractions; and LP2, high-speed pellet of lysed synaptosomes containing synaptic vesicles. Blots were probed with the antibodies indicated at the right.
|
|
|
|---|
Specialized septin complexes may also exist in more complex organisms as well. In mammalian cells, at least 11 different septin genes have been identified, several of which have multiple splice forms. Some of these appear to have broad expression patterns while others have unique, tissue-specific patterns. CDCrel-1 and G-septin are primarily expressed in the brain (2, 5, 41) while most of the other forms are broadly expressed (unpublished observations). These complex expression patterns may result in the assembly of distinct septin complexes in each cell type that could possess the combined properties contributed by each of its members. We have shown here that CDCrel-1 can be immunoprecipitated from the brain in a complex that includes Nedd5 and CDC10 but not H5.
The targeted disruption of CDCrel-1 in mice has no overt developmental or neurophysiological consequences. This is surprising given the number of linkages of CDCrel-1 to disease and neuronal function. First, CDCrel-1 had been identified within the locus that is commonly deleted in patients with DiGeorge syndrome (28). In these individuals, haploinsufficiency of an approximately 3-Mb region is often seen, and it had been assumed that a single gene within this locus might have caused the complex phenotypes associated with this syndrome. More recent studies have implicated the T-box transcription factor Tbx1 as a major cause of this syndrome, although the loss of other genes in the locus may also contribute to the phenotype (26, 29). However, our data indicate that despite its position within the deleted locus, the loss of one or both copies of the CDCrel-1 gene is unlikely to contribute significantly to the development of this disorder.
Recent evidence has also linked CDCrel-1 to the neurodegenerative disorder Parkinsons disease on the basis of its binding and ubiquitination by the E3 ubiquitin ligase Parkin (42). Parkin is the gene product linked to autosomal recessive forms of Parkinsons disease due to point mutations or deletions that result in the loss of function of this protein. The discovery that CDCrel-1 may be a target of Parkin led to suggestions that one of the contributing factors in Parkinsons disease may be the failure to degrade CDCrel-1 (42). Because it had previously been shown that CDCrel-1 overexpression inhibits secretion, the possibility was raised that failure to eliminate CDCrel-1 by ubiquitin-mediated degradation may contribute to Parkinsons disease by limiting the release of dopamine from neurons of the substantia nigra. We have seen no motor or neurological disorders in these mice, but based on this hypothesis we might expect that the CDCrel-1-deficient mice would be less prone to Parkinsonian disorders. It will be of interest to examine the relative sensitivity of the CDCrel-1-deficient mice to conditions that mimic or induce loss of substantia nigra cells.
It had previously been shown that CDCrel-1 was colocalized with the syntaxin and SNAP-25 tSNARE proteins in PC12 cells (2), and we have shown here that it is present in synaptic sites overlapping with the presence of synaptic vesicles. This distribution is consistent with recently published immunoelectron microscopic data that demonstrated the presence of CDCrel-1 among vesicles within presynaptic nerve terminals, particularly in inhibitory neurons (22). Our previous observations that dominant-negative forms of CDCrel-1 caused enhanced secretion led to our hypothesis that CDCrel-1-deficient mice would exhibit enhanced neurotransmitter release or reveal evidence of synaptic depression due to depleted synaptic vesicle stores. At least two possibilities could account for the lack of such resultsdifferent phenotypes resulting from the dominant-negative and null mutation approaches or compensatory changes that may not be seen in acute transfection experiments but that could occur during mouse development.
The previous dominant-negative approach was based on the observations of Kinoshita et al. (23) and our own unpublished results showing that GTP binding and/or hydrolysis may be necessary for the formation of septin polymers. Mutations that inhibit GTP binding prevented filament assembly and thereby appeared to act in a dominant-negative manner, possibly by competing with endogenous CDCrel-1. However, we cannot rule out the possibility that the dominant-negative approach affects the function of all endogenous septins while the null mutation only eliminates the function of just one of them. In this case, redundancy could account for the lack of phenotype. Evidence for functional redundancy among the septins has been observed in Drosophila. In this case, both female germ cell division and early stages of embryo cellularization occur normally in the absence of the septin peanut, suggesting either that it is not required for these steps or that other septins may compensate for its loss (1). In the case of Caenorhabditis elegans, mutations in either of the two known septins, unc-59 or unc-61, resulted in the same phenotype. Mutations in either gene disrupted the localization of the other septin to the cleavage furrow and prevented postembryonic but not embryonic cytokinesis (31). Whether this indicates a lack of a role for these septins in embryonic cytokinesis or the presence of unknown proteins with redundant septin functions remains to be seen.
Aside from direct functional redundancy, an alternative form of redundancy could be achieved if alterations in the expression of other septins could compensate for the loss of a particular one. Analysis of the mice deficient in CDCrel-1 clearly shows that they have altered levels of other septin proteins in the brain. At the protein level, decreased amounts of CDC10 could reflect increased rates of degradation if the lack of CDCrel-1 decreased its stability. Alternatively, if CDCrel-1 is degraded due to its interaction with Parkin, associated proteins may suffer the same fate. Hence, in the absence of CDCrel-1, elevated Nedd5 levels could result from decreased degradation. However, as Nedd5 and CDC10 appear to be present within the same coimmunoprecipitating complex, it is unclear why their relative levels would have changed in opposite directions. Another explanation is that a change in the pattern of septin transcription that has occurred in the knockout mice permits the assembly of alternative combinations of septins with compensatory functions. In either case, our data demonstrate that CDCrel-1 is not required for neuronal development or regulated neurotransmission.
This work was supported by a grant from the Canadian Institutes of Health Research to W.S.T. X.-R.P. was supported by a fellowship from the Research Training Centre of the Hospital for Sick Children. Z.J. is a New Investigator and W.S.T. is an Investigator of the CIHR.
Present address: Department of Molecular Biology, AstraZeneca, S-431 83, Mölndal, Sweden. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»